Literature DB >> 3581568

Revision knee arthroplasty in rheumatoid arthritis.

B Rööser, T Boegård, K Knutson, U Rydholm, L Lidgren.   

Abstract

Seventy-six revised total knee arthroplasties (TKAs) performed for mechanical, nonseptic failure of the primary arthroplasty in 62 rheumatoid arthritis patients were investigated. The revisions were performed with McIntosh, Marmor, Attenborough, Guepar, and various types of tricompartmental prostheses. Twenty-one of the 76 revisions subsequently failed. Fifteen were mechanical failures and six were deep infections. Thirteen of the 21 failures were treated with another arthroplasty, six with arthrodesis, and two with antibiotics only. After an average of 60 months, 48 of the surviving arthroplasties were examined clinically and roentgenographically. At follow-up examination, eight were clinical failures. One-half of the McIntosh and Marmor arthroplasties and one-third of the Attenborough and Guepar arthroplasties, altogether 17 cases, showed signs of potential roentgenographic failure. The majority of the revised TKAs classified as roentgenographic failures were clinically successful or acceptable. Revision of TKAs in noninfected rheumatoid patients can be performed with acceptable clinical results but with a significantly higher failure rate than after primary procedures.

Entities:  

Mesh:

Year:  1987        PMID: 3581568

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  2 in total

1.  Revision total knee arthroplasty for aseptic and septic causes in patients with rheumatoid arthritis.

Authors:  Ryan M Garcia; Brian T Hardy; Matthew J Kraay; Victor M Goldberg
Journal:  Clin Orthop Relat Res       Date:  2010-01       Impact factor: 4.176

2.  Outcome of knee revisions for osteoarthritis and inflammatory arthritis with postero-stabilized arthroplasties: a mean ten-year follow-up with 90 knee revisions.

Authors:  Philippe Hernigou; Arnaud Dubory; Damien Potage; François Roubineau; Charles Henri Flouzat-Lachaniette
Journal:  Int Orthop       Date:  2016-10-27       Impact factor: 3.075

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.